ClinicalTrials.gg
CompletedNCT02958865Updated Jul 21, 2022Results posted

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

A Phase 2 interventional study of PF-06651600 or Placebo and PF-06700841 or Placebo in Ulcerative Colitis, sponsored by Pfizer. Completed at 189 sites in 19 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-07-21.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
319
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Colitis, Ulcerative by Pfizer — 3 open to participants now, 7 under way, 2 of them phase 3. Colitis, Ulcerative · Pfizer.

Enrollment
8th of 24
319 · median 129
Started
2017
with 2 others
Phase 2
12 of 42
2 open now
Registered
14th of 42
by date

Among the 42 studies in Colitis, Ulcerative by Pfizer, this one is the 8th largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2017, is one of 12 in phase 2, and was the 14th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 42 studies in Colitis, Ulcerative by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Colitis, Ulcerative by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether PF-06651600 and PF-06700841 are effective in treatment of moderate to severe ulcerative colitis.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Mayo score
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ulcerative colitis for greater than/equal to 3 months.
  • Moderate to severe active ulcerative colitis
  • Inadequate response to, loss of response to, or intolerance to at least one conventional therapy for UC.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Clinical findings suggestive of Crohn's Disease
  • History of bowel surgery within 6 months
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
319 participants (actual)

Study arms

  • Experimental
    PF-06651600 Drug Dose Level 1

    Delivered orally for 8 weeks

    Drug: PF-06651600 or Placebo

  • Experimental
    PF-06651600 Drug Dose Level 2

    Delivered orally for 8 weeks

    Drug: PF-06651600 or Placebo

  • Experimental
    PF-06651600 Drug Dose Level 3

    Delivered orally for 8 weeks.

    Drug: PF-06651600 or Placebo

  • Placebo comparator
    PF-06651600 Placebo

    Delivered orally for 8 weeks.

    Drug: PF-06651600 or Placebo

  • Experimental
    PF-06700841 Drug Dose Level 1

    Delivered orally for 8 weeks

    Drug: PF-06700841 or Placebo

  • Experimental
    PF-06700841 Drug Dose Level 2

    Delivered orally for 8 weeks.

    Drug: PF-06700841 or Placebo

  • Experimental
    PF-06700841 Drug Dose Level 3

    Delivered orally for 8 weeks.

    Drug: PF-06700841 or Placebo

  • Placebo comparator
    PF-06700841 Placebo

    Delivered orally for 8 weeks.

    Drug: PF-06700841 or Placebo

  • Experimental
    PF-06651600 Drug Dose Level 4

    Delivered orally for 24 weeks.

    Drug: PF-06651600

  • Experimental
    PF-06700841 Drug Dose Level 4

    Delivered orally for 24 weeks.

    Drug: PF-06700841

Interventions

  • DrugPF-06651600 or Placebo

    Delivered orally for 8 weeks.

  • DrugPF-06700841 or Placebo

    Delivered orally for 8 weeks.

  • Delivered orally for 24 weeks.

  • Delivered orally for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Total Mayo Score at Week 8 (Induction Period)

    The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicates more severe disease activity and lower score denotes improvement of disease activity as measured by the total Mayo score.

    Time frame: Week 8

Secondary outcomes

  1. Number of Participants With AEs, SAEs and Discontinuation Due to AEs (Chronic Period)

    An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes: death, life-threatening experience, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. All AEs mentioned below are treatment-emergent AEs.

    Time frame: From Week 8 up to Week 32

  2. Number of Participants With Laboratory Test Abnormalities (Chronic Period)

    The number of participants with a laboratory abnormality meeting the pre-specified criteria defined in the study protocol while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. Laboratory data included hematology test, serum chemistry test, C-creative protein and viral surveillance.

    Time frame: From Week 8 to Week 32

  3. Number of Participants With Laboratory Test Abnormalities-hematology (Chronic Period)

    The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of hematology test parameters were as follows: hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils (absolute, Abs), eosinophils (Abs), monocytes (Abs), basophils (Abs), lymphocytes (Abs), prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT), and reticulocytes (% and Abs). Percentages are displayed for the laboratory tests having a category with greater or equal to 1 evaluable participant.

    Time frame: From Week 8 to Week 32

  4. Number of Participants With Abnormal Vital Signs Data (Chronic Period)

    The vital signs data included the single sitting blood pressure, pulse rate and temperature. The criteria of vital sign abnormality are indicated below.

    Time frame: From Week 8 to Week 32

  5. Number of Participants With Abnormal ECG Findings (Chronic Period)

    The number of participants with abnormal ECG findings during the chronic period (from Week 9 to Week 32) are reported below.

    Time frame: Week 8 to Week 32

  6. Number of Participants With Serious Infections (Chronic Period)

    Serious infections was defined as any infection (for example, viral, bacterial, and fungal) requiring hospitalization or parenteral antimicrobials.

    Time frame: Week 8 to Week 32

  7. Number of Participants With Laboratory Test Abnormalities-clinical Chemistry (Chronic Period)

    The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of serum chemistry test parameters were as follows: blood urea nitrogen, creatinine, cystatin C, glucose, calcium, sodium, potassium, gamma glutamyl transferase, chloride, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, alkaline phosphatase, uric acid, albumin, total protein, creatine kinase (CK), total cholesterol, triglycerides, high-density lipoproteins (HDL), and low-density lipoprotein (LDL).

    Time frame: Week 8 to Week 32

  8. Number of Participants With Laboratory Test Abnormalities-urinalysis (Chronic Period)

    The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of urinalysis test parameters were as follows:pH, glucose (qual), protein (qual), blood (qual), ketones, nitrites, leukocyte esterase, microscopy, and spot urine albumin/creatinine ratio. The criteria of laboratory abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.

    Time frame: Week 8 to Week 32

  9. Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs (All-causalities) (Induction Period)

    An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes: death, life-threatening experience, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. All AEs mentioned below are treatment-emergent AEs.

    Time frame: From Day 1 up to Week 8

  10. Number of Participants With Laboratory Test Abnormalities (Induction Period)

    The number of participants with a laboratory abnormality meeting the pre-specified criteria defined in the study protocol while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. Laboratory data included hematology test, serum chemistry test, C-creative protein and viral surveillance. The criteria of laboratory abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.

    Time frame: From Day 1 up to Week 8

  11. Number of Participants With Laboratory Test Abnormalities-hematology (Induction Period)

    The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of hematology test parameters were as follows: hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils (absolute, Abs), eosinophils (Abs), monocytes (Abs), basophils (Abs), lymphocytes (Abs), prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT), and reticulocytes (% and Abs). Percentages are displayed for the laboratory tests having a category with greater or equal to 1 evaluable participant.

    Time frame: From Day 1 up to Week 8

  12. Number of Participants With Laboratory Test Abnormalities-clinical Chemistry (Induction Period)

    The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of serum chemistry test parameters were as follows: blood urea nitrogen, creatinine, cystatin C, glucose, calcium, sodium, potassium, gamma glutamyl transferase, chloride, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, alkaline phosphatase, uric acid, albumin, total protein, creatine kinase (CK), total cholesterol, triglycerides, high-density lipoproteins (HDL), and low-density lipoprotein (LDL)

    Time frame: From Day 1 up to Week 8

  13. Number of Participants With Laboratory Test Abnormalities- Urinalysis (Induction Period)

    The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of urinalysis test parameters were as follows:pH, glucose (qual), protein (qual), blood (qual), ketones, nitrites, leukocyte esterase, microscopy, and spot urine albumin/creatinine ratio. The criteria of laboratory abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.

    Time frame: From Day 1 up to Week 8

  14. Number of Participants With Abnormal Vital Signs Data (Induction Period)

    The vital signs data included the single sitting blood pressure, pulse rate and temperature. The criteria of vital sign abnormality are indicated below.

    Time frame: From screening to Week 8

  15. Number of Participants With Abnormal Electrocardiogram (ECG) Findings (Induction Period)

    The number of participants with abnormal ECG findings during the induction period (from Day 1 to Week 8) are reported below. The criteria of test abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.

    Time frame: From screening to Week 8

  16. Number of Participants With Serious Infections (Induction Period)

    Serious infections was defined as any infection (for example, viral, bacterial, and fungal) requiring hospitalization or parenteral antimicrobials including Listeria encephalitis, Pneumonia, Viral infection.

    Time frame: From Day 1 up to Week 8

  17. Percentage of Participants Achieving Remission Based on Total Mayo Score at Week 8 (Induction Period)

    The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Clinical remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0.

    Time frame: Week 8

  18. Percentage of Participants Achieving Improvement in Endoscopic Appearance Based on Total Mayo Score at Week 8 (Induction Period)

    The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Improvement in endoscopic subscore appearance was defined at Mayo endoscopic subscore of ≤1.

    Time frame: Week 8

  19. Percentage of Participants Achieving Clinical Response Based on Total Mayo Score at Week 8 (Induction Period)

    The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Clinical response was defined as decrease from baseline in total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or absolute subscore for rectal bleeding of 0 or 1.

    Time frame: Week 8

  20. Percentage of Participants Achieving Endoscopic Remission Based on Total Mayo Score at Week 8 (Induction Period)

    The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Endoscopic remission was defined as endoscopic subscore of 0.

    Time frame: Week 8

  21. Percentage of Participants Achieving Symptomatic Remission Based on Total Mayo Score at Week 8 (Induction Period)

    The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Symptomatic remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and both rectal bleeding and stool frequency subscores of 0.

    Time frame: Week 8

  22. Percentage of Participants Achieving Deep Remission Based on Total Mayo Score at Week 8 (Induction Period)

    The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Deep remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a zero on both endoscopic and rectal bleeding subscore.

    Time frame: Week 8

  23. Partial Mayo Score and Change From Baseline at Weeks 2, 4 and 8 (Induction Period)

    The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. The partial Mayo score does not incorporate the endoscopy score and the partial Mayo score ranges from 0 to 9.

    Time frame: Baseline, Weeks 2, 4 and 8

  24. Change From Baseline in Total Mayo Score at Week 8 (Induction Period)

    The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity.

    Time frame: Baseline, Week 8

  25. Inflammatory Bowel Disease Questionnaire (IBDQ) Domain Score and Total Score at Weeks 4 and 8 (Induction Period)

    IBDQ is a psychometrically validated patient reported outcome (PRO) instrument for measuring the disease specific quality of life in participants with inflammatory bowel disease (IBD). The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life.

    Time frame: Week 4 and Week 8

  26. Change From Baseline in IBDQ Total Score at Weeks 4 and 8 (Induction Period)

    IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life. Baseline value is defined as the last non-missing measurement collected prior to or on Day 1.

    Time frame: Baseline, Weeks 4 and 8

  27. Percentage of Participants With IBDQ Total Score Greater Than or Equal to 170 at Weeks 4 and 8 (Induction Period)

    IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life.

    Time frame: Week 4 and Week 8

  28. Percentage of Participants With Greater Than or Equal to 16 Points Increase in IBDQ Total Score From Baseline at Weeks 4 and 8 (Induction Period)

    IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life.

    Time frame: Baseline, Week 4 and 8

  29. Percentage of Participants With Improvement in IBDQ Bowel Symptom Domain at Weeks 4 and 8 (Induction Period)

    IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life. The improvement in IBDQ bowel symptom domain was defined as an increase of ≥1.2 points from baseline in average score among bowel symptoms domain (items 1, 5, 9, 13, 17, 20, 22, 24, 26, 29).

    Time frame: Week 4 and Week 8

  30. Change From Baseline in Short Form 36 Version 2 (SF-36v2) Acute Mental Component Summary (MCS) Score and Physical Component Summary (PCS) Score at Weeks 4 and 8 (Induction Period)

    The SF-36 version 2 (Acute version) is a 36-item generic health status measure. It measures 8 general health concepts or domains: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH). These 8 domains can also be summarized as physical and mental component scores. The summary component scores, Physical Component Summary (PCS) and Mental Component Summary (MCS), are based on a normalized sum of the 8 scale scores PF, RP, BP, GH, VT, SF, RE, and MH . All domains and summary components are scored such that a higher score indicates a higher functioning or health level. The minimum and maximum scores of the PCS Score are 6.1 and 79.7, respectively. The minimum and maximum scores of the MCS Score are -3.8 and 78.7, respectively.

    Time frame: Week 4 and Week 8

  31. Change From Baseline in Euro Quality of Life Questionnaire 5 Dimensions 3 Levels (EQ-5D 3L) Utility Score and EQ-5D Visual Analog Scale (VAS) at Weeks 4 and 8 (Induction Period)

    For EQ-5D 3L, participant rated questionnaire to assess generic health status in two parts: single utility score and visual analog scale. For utility score, participants rated their current health state on 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression with each dimension having three levels of function: 1 indicates no problem; 2 indicates some problem; 3 indicates extreme problem. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score was transformed and results in a total score range of 0.05 to 1.00; higher scores indicating a better health state. The EQ-5D VAS records the respondent's self rated health on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state).

    Time frame: Week 4 and Week 8

  32. Total Mayo Score at Week 32 (Chronic Period)

    The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity.

    Time frame: Week 32

  33. Percentage of Participants Achieving Remission Based on Total Mayo Score at Week 32 (Chronic Period)

    The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Clinical remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0.

    Time frame: Week 32

  34. Percentage of Participants Achieving Improvement in Endoscopic Appearance Based on Mayo Score at Week 32 (Chronic Period)

    The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Improvement in endoscopic appearance was defined at Mayo endoscopic subscore of ≤1.

    Time frame: Week 32

Other outcomes

  1. Change From Baseline in Total Mayo Score at Week 32 (Chronic Period)

    The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity.

    Time frame: Week 32

07

Results

Posted Jul 21, 2022

Participant flow

The study consisted of a screening period of up to 6 weeks, an 8-week double-blind induction period, and an additional 24-week open-label active chronic dosing period followed by a 4-week follow up period after the last dose of investigational product.

Induction Period (Day 1 to Week 8)
Participant flow — Induction Period (Day 1 to Week 8)
MilestonePlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)PF-06651600 200 mg -> PF-06651600 50 mgPF-06651600 70 mg -> PF-06651600 50 mgPF-06651600 20 mg -> PF-06651600 50 mgPlacebo -> PF-06651600 50 mgPF-06700841 60 mg -> PF-06700841 30 mgPF-06700841 30 mg -> PF-06700841 30 mgPF-06700841 10 mg -> PF-06700841 30 mgPlacebo -> PF-06700841 30 mgPooling Placebo During Chronic
Started25514950484747000000000
Completed21444341454344000000000
Not completed4769343000000000
Withdrew: Adverse event0405121000000000
Withdrew: Death0100000000000000
Withdrew: Physician decision1100000000000000
Withdrew: Withdrawal by subject2031111000000000
Withdrew: No longer meeting eligibility criteria0001001000000000
Withdrew: Protocol violation0010000000000000
Withdrew: Lack of efficacy1110000000000000
Withdrew: Other0012010000000000
Withdrew: Lost to follow-up0000100000000000
Chronic Period (Week 8 to Week 32)
Participant flow — Chronic Period (Week 8 to Week 32)
MilestonePlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)PF-06651600 200 mg -> PF-06651600 50 mgPF-06651600 70 mg -> PF-06651600 50 mgPF-06651600 20 mg -> PF-06651600 50 mgPlacebo -> PF-06651600 50 mgPF-06700841 60 mg -> PF-06700841 30 mgPF-06700841 30 mg -> PF-06700841 30 mgPF-06700841 10 mg -> PF-06700841 30 mgPlacebo -> PF-06700841 30 mgPooling Placebo During Chronic
Started000000035363910383739937
Completed000000033333310312631520
Not completed000000023607118417
Withdrew: Adverse event0000000112014115
Withdrew: Lack of efficacy0000000021050208
Withdrew: Pregnancy0000000001000001
Withdrew: Withdrawal by subject0000000000016332
Withdrew: Other0000000101001001
Withdrew: Non-compliance with study drug0000000000000100
Withdrew: Protocol violation0000000000000100
Withdrew: No longer meeting eligibility criteria0000000001000000

Outcome measures

PrimaryTotal Mayo Score at Week 8 (Induction Period)

The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicates more severe disease activity and lower score denotes improvement of disease activity as measured by the total Mayo score.

Time frame:
Week 8
Reported as:
Least squares mean · Units on a scale
Total Mayo Score at Week 8 (Induction Period)
Units on a scalePlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Total Mayo Score at Week 8 (Induction Period)7.88 (6.95 to 8.81)5.85 (5.18 to 6.51)4.00 (3.33 to 4.67)3.27 (2.58 to 3.96)6.08 (5.43 to 6.74)5.60 (4.93 to 6.27)4.67 (4.01 to 5.33)
Statistical analysis
  • Placebo (Induction) vs PF-06651600 20 mg (Induction) · Constrained Longitudinal Data Analysis · p = 0.0017 · Mean difference (final values): -2.03 · 90% CI -3.17 to -0.89
  • Placebo (Induction) vs PF-06651600 70 mg (Induction) · Constrained Longitudinal Data Analysis · p = < 0.0001 · Mean difference (final values): -3.88 · 90% CI -5.01 to -2.74
  • Placebo (Induction) vs PF-06651600 200 mg (Induction) · Constrained Longitudinal Data Analysis · p = < 0.0001 · Mean difference (final values): -4.61 · 90% CI -5.76 to -3.46
  • Placebo (Induction) vs PF-06700841 10 mg (Induction) · Constrained Longitudinal Data Analysis · p = 0.0045 · Mean difference (final values): -1.79 · 90% CI -2.92 to -0.67
  • Placebo (Induction) vs PF-06700841 30 mg (Induction) · Constrained Longitudinal Data Analysis · p = 0.0005 · Mean difference (final values): -2.28 · 90% CI -3.41 to -1.14
  • Placebo (Induction) vs PF-06700841 60 mg (Induction) · Constrained Longitudinal Data Analysis · p = < 0.0001 · Mean difference (final values): -3.21 · 90% CI -4.34 to -2.08
SecondaryNumber of Participants With AEs, SAEs and Discontinuation Due to AEs (Chronic Period)

An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes: death, life-threatening experience, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. All AEs mentioned below are treatment-emergent AEs.

Time frame:
From Week 8 up to Week 32
Reported as:
Count of participants · Participants
Number of Participants With AEs, SAEs and Discontinuation Due to AEs (Chronic Period)
ParticipantsPF-06651600 200 mg -> PF-06651600 50 mgPF-06651600 70 mg -> PF-06651600 50 mgPF-06651600 20 mg -> PF-06651600 50 mgPlacebo -> PF-06651600 50 mgPF-06700841 60 mg -> PF-06700841 30 mgPF-06700841 30 mg -> PF-06700841 30 mgPF-06700841 10 mg -> PF-06700841 30 mgPlacebo -> PF-06700841 30 mgPooling Placebo During Chronic
Participants with AEs1827188212326418
Participants with SAEs311024200
Participants discontinued from study due to AEs113114116
SecondaryNumber of Participants With Laboratory Test Abnormalities (Chronic Period)

The number of participants with a laboratory abnormality meeting the pre-specified criteria defined in the study protocol while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. Laboratory data included hematology test, serum chemistry test, C-creative protein and viral surveillance.

Time frame:
From Week 8 to Week 32
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities (Chronic Period)
ParticipantsPF-06651600 200 mg -> PF-06651600 50 mgPF-06651600 70 mg -> PF-06651600 50 mgPF-06651600 20 mg -> PF-06651600 50 mgPlacebo -> PF-06651600 50 mgPF-06700841 60 mg -> PF-06700841 30 mgPF-06700841 30 mg -> PF-06700841 30 mgPF-06700841 10 mg -> PF-06700841 30 mgPlacebo -> PF-06700841 30 mgPooling Placebo During Chronic
Number of Participants With Laboratory Test Abnormalities (Chronic Period)2731338292728823
SecondaryNumber of Participants With Laboratory Test Abnormalities-hematology (Chronic Period)

The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of hematology test parameters were as follows: hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils (absolute, Abs), eosinophils (Abs), monocytes (Abs), basophils (Abs), lymphocytes (Abs), prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT), and reticulocytes (% and Abs). Percentages are displayed for the laboratory tests having a category with greater or equal to 1 evaluable participant.

Time frame:
From Week 8 to Week 32
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities-hematology (Chronic Period)
ParticipantsPF-06651600 200 mg -> PF-06651600 50 mgPF-06651600 70 mg -> PF-06651600 50 mgPF-06651600 20 mg -> PF-06651600 50 mgPlacebo -> PF-06651600 50 mgPF-06700841 60 mg -> PF-06700841 30 mgPF-06700841 30 mg -> PF-06700841 30 mgPF-06700841 10 mg -> PF-06700841 30 mgPlacebo -> PF-06700841 30 mgPooling Placebo During Chronic
Hemoglobin (g/dL) <0.8× LLN221133623
Hematocrit (%) <0.8× LLN021011112
Erythrocytes (10^6/mm^3) <0.8× LLN011010111
Reticulocytes (Abs) (10^3/mm^3) >1.5× ULN001000000
Erythrocytes Mean Corpuscular Volume (10^-15L) <0.9× LLN001001000
Platelets (10^3/mm^3) >1.75× ULN000031202
Reticulocytes/Erythrocytes (%) >1.5× ULN112011001
Leukocytes (10^3/mm^3) >1.5× ULN001111111
Lymphocytes (Abs) (10^3/mm^3) <0.8× LLN766100303
Lymphocytes (Abs) (10^3/mm^3) >1.2× ULN000000010
Neutrophils (Abs) (10^3/mm^3) <0.8× LLN120031211
Neutrophils (Abs) (10^3/mm^3) >1.2× ULN3811186636
Basophils (Abs) (10^3/mm^3) >1.2× ULN000021001
Eosinophils (Abs) (10^3/mm^3) >1.2x ULN000021002
Monocytes (Abs) (10^3/mm^3) >1.2× ULN000022000
Activated PTT (second) >1.1× ULN031020000
PT (second) >1.1× ULN232022000
Prothrombin INR >1.1× ULN232021000
SecondaryNumber of Participants With Abnormal Vital Signs Data (Chronic Period)

The vital signs data included the single sitting blood pressure, pulse rate and temperature. The criteria of vital sign abnormality are indicated below.

Time frame:
From Week 8 to Week 32
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Vital Signs Data (Chronic Period)
ParticipantsPF-06651600 200 mg -> PF-06651600 50 mgPF-06651600 70 mg -> PF-06651600 50 mgPF-06651600 20 mg -> PF-06651600 50 mgPlacebo -> PF-06651600 50 mgPF-06700841 60 mg -> PF-06700841 30 mgPF-06700841 30 mg -> PF-06700841 30 mgPF-06700841 10 mg -> PF-06700841 30 mgPlacebo -> PF-06700841 30 mgPooling Placebo During Chronic
Sitting Systolic Blood Pressure Value <90 mmHg001000101
Sitting Systolic Blood Pressure Change ≥30 mmHg Increase034032303
Sitting Systolic Blood Pressure Change ≥30 mmHg Decrease000011001
Sitting Diastolic Blood Pressure Value <50 mmHg000000000
Sitting Diastolic Blood Pressure Change ≥20 mmHg Increase016142111
Sitting Diastolic Blood Pressure Change ≥20 mmHg Decrease245023102
Sitting Pulse Rate Value <40 beat per minute (bpm)000000000
Sitting Pulse Rate Value >120 bpm001000000
SecondaryNumber of Participants With Abnormal ECG Findings (Chronic Period)

The number of participants with abnormal ECG findings during the chronic period (from Week 9 to Week 32) are reported below.

Time frame:
Week 8 to Week 32
Reported as:
Count of participants · Participants
Number of Participants With Abnormal ECG Findings (Chronic Period)
ParticipantsPF-06651600 200 mg -> PF-06651600 50 mgPF-06651600 70 mg -> PF-06651600 50 mgPF-06651600 20 mg -> PF-06651600 50 mgPlacebo -> PF-06651600 50 mgPF-06700841 60 mg -> PF-06700841 30 mgPF-06700841 30 mg -> PF-06700841 30 mgPF-06700841 10 mg -> PF-06700841 30 mgPlacebo -> PF-06700841 30 mgPooling Placebo During Chronic
Abnormal, not clinically significant362112424
Abnormal, clinically significant000000000
SecondaryNumber of Participants With Serious Infections (Chronic Period)

Serious infections was defined as any infection (for example, viral, bacterial, and fungal) requiring hospitalization or parenteral antimicrobials.

Time frame:
Week 8 to Week 32
Reported as:
Count of participants · Participants
Number of Participants With Serious Infections (Chronic Period)
ParticipantsPF-06651600 200 mg -> PF-06651600 50 mgPF-06651600 70 mg -> PF-06651600 50 mgPF-06651600 20 mg -> PF-06651600 50 mgPlacebo -> PF-06651600 50 mgPF-06700841 60 mg -> PF-06700841 30 mgPF-06700841 30 mg -> PF-06700841 30 mgPF-06700841 10 mg -> PF-06700841 30 mgPlacebo -> PF-06700841 30 mgPooling Placebo During Chronic
COVID-19 pneumonia000000100
Viral infection000010000
SecondaryNumber of Participants With Laboratory Test Abnormalities-clinical Chemistry (Chronic Period)

The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of serum chemistry test parameters were as follows: blood urea nitrogen, creatinine, cystatin C, glucose, calcium, sodium, potassium, gamma glutamyl transferase, chloride, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, alkaline phosphatase, uric acid, albumin, total protein, creatine kinase (CK), total cholesterol, triglycerides, high-density lipoproteins (HDL), and low-density lipoprotein (LDL).

Time frame:
Week 8 to Week 32
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities-clinical Chemistry (Chronic Period)
ParticipantsPF-06651600 200 mg -> PF-06651600 50 mgPF-06651600 70 mg -> PF-06651600 50 mgPF-06651600 20 mg -> PF-06651600 50 mgPlacebo -> PF-06651600 50 mgPF-06700841 60 mg -> PF-06700841 30 mgPF-06700841 30 mg -> PF-06700841 30 mgPF-06700841 10 mg -> PF-06700841 30 mgPlacebo -> PF-06700841 30 mgPooling Placebo During Chronic
Bilirubin (mg/dL) >1.5 x ULN101010101
Direct Bilirubin (mg/dL) >1.5 x ULN000000000
Indirect Bilirubin (mg/dL) >1.5 x ULN000000000
AST (U/L) >3.0 x ULN002000000
ALT (U/L) >3.0 x ULN101000200
Gamma Glutamyl Transferase (U/L) >3.0 x ULN000000000
Alkaline Phosphatase (U/L) >3.0 x ULN001000000
Protein (g/dL) <0.8 x LLN000000000
Protein (g/dL) >1.2 x ULN000000000
Albumin (g/dL) <0.8 x LLN000000000
Albumin (g/dL) >1.2 x ULN000000000
Urea Nitrogen (mg/dL) >1.3 x ULN010000000
Creatinine (mg/dL) >1.3 x ULN010001100
Urate (mg/dL) >1.2 x ULN020001100
HDL Cholesterol (mg/dL) <0.8 x LLN100000100
LDL Cholesterol (mg/dL) >1.2 x ULN110010210
Triglycerides (mg/dL) >1.3 x ULN321022101
Sodium (Meq/L) <0.95 x LLN000000000
Sodium (Meq/L) >1.05 x ULN000000000
Potassium (Meq/L) <0.9 x LLN000001000
Potassium (Meq/L) >1.1 x ULN100020000
Chloride (Meq/L) <0.9 x LLN000000000
Chloride (Meq/L) >1.1 x ULN000000000
Calcium (mg/dL) <0.9 x LLN000001000
Calcium (mg/dL) >1.1 x ULN000000000
Glucose (mg/dL) <0.6 x LLN000000000
Glucose (mg/dL) >1.5 x ULN133012000
Hemoglobin A1C (%) >1.3 x ULN000000000
Creatine Kinase (U/L) >2.0 x ULN1321310201
Cholesterol (mg/dl) >1.3 x ULN010000100
SecondaryNumber of Participants With Laboratory Test Abnormalities-urinalysis (Chronic Period)

The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of urinalysis test parameters were as follows:pH, glucose (qual), protein (qual), blood (qual), ketones, nitrites, leukocyte esterase, microscopy, and spot urine albumin/creatinine ratio. The criteria of laboratory abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.

Time frame:
Week 8 to Week 32
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities-urinalysis (Chronic Period)
ParticipantsPF-06651600 200 mg -> PF-06651600 50 mgPF-06651600 70 mg -> PF-06651600 50 mgPF-06651600 20 mg -> PF-06651600 50 mgPlacebo -> PF-06651600 50 mgPF-06700841 60 mg -> PF-06700841 30 mgPF-06700841 30 mg -> PF-06700841 30 mgPF-06700841 10 mg -> PF-06700841 30 mgPlacebo -> PF-06700841 30 mgPooling Placebo During Chronic
pH (scalar) <4.5000000000
pH (scalar) >8000000000
Urine Glucose (No Unit) >=1121111001
Ketones (No Unit) >=1438241302
Urine Protein (No Unit) >=1013010201
Urine Hemoglobin (No Unit) >=1745179909
Nitrite (No Unit) >=1220211101
Leukocyte Esterase (No Unit) >=1813111147819
Urine Erythrocytes (/HPF) >=20114123501
Urine Leukocytes (/HPF) >=20023131104
Hyaline Casts (/LPF) >1506241212
WBC Casts (/LPF) >1000000001
Bacteria (No Unit) >20000000100
SecondaryNumber of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs (All-causalities) (Induction Period)

An AE was an untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes: death, life-threatening experience, initial or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect. Treatment-emergent AEs were those with initial onset or that worsen in severity after the first dose of study medication. All AEs mentioned below are treatment-emergent AEs.

Time frame:
From Day 1 up to Week 8
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Discontinuation Due to AEs (All-causalities) (Induction Period)
ParticipantsPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Participants with AEs13232121192623
Participants with SAEs0303131
Participants discontinued from study due to AEs0505121
SecondaryNumber of Participants With Laboratory Test Abnormalities (Induction Period)

The number of participants with a laboratory abnormality meeting the pre-specified criteria defined in the study protocol while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. Laboratory data included hematology test, serum chemistry test, C-creative protein and viral surveillance. The criteria of laboratory abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.

Time frame:
From Day 1 up to Week 8
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities (Induction Period)
ParticipantsPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Number of Participants With Laboratory Test Abnormalities (Induction Period)17292834323136
SecondaryNumber of Participants With Laboratory Test Abnormalities-hematology (Induction Period)

The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of hematology test parameters were as follows: hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils (absolute, Abs), eosinophils (Abs), monocytes (Abs), basophils (Abs), lymphocytes (Abs), prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time (PTT), and reticulocytes (% and Abs). Percentages are displayed for the laboratory tests having a category with greater or equal to 1 evaluable participant.

Time frame:
From Day 1 up to Week 8
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities-hematology (Induction Period)
ParticipantsPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Hemoglobin (g/dL) <0.8× lower limit of normal (LLN)3259445
Hematocrit (%) <0.8× LLN2034110
Erythrocytes (10^6/mm^3) <0.8× LLN0043112
Reticulocytes (Abs) (10^3/mm^3) <0.5× LLN0000000
Reticulocytes (Abs) (10^3/mm^3) >1.5× upper limit of normal (ULN)1122000
Erythrocytes Mean Corpuscular Volume (10^-15L) <0.9× LLN0000000
Erythrocytes Mean Corpuscular Volume (10^-15L) >1.1× ULN0000000
Platelets (10^3/mm^3) <0.5× LLN0000000
Platelets (10^3/mm^3) >1.75× ULN1000225
Reticulocytes/Erythrocytes (%) <0.5× LLN0000000
Reticulocytes/Erythrocytes (%) >1.5× ULN1233002
Leukocytes (10^3/mm^3) <0.6× LLN0000100
Leukocytes (10^3/mm^3) >1.5× ULN0303221
Lymphocytes (Abs) (10^3/mm^3) <0.8× LLN32411212
Lymphocytes (Abs) (10^3/mm^3) >1.2× ULN0100111
Neutrophils (Abs) (10^3/mm^3) <0.8× LLN1000232
Neutrophils (Abs) (10^3/mm^3) >1.2× ULN713797711
Basophils (Abs) (10^3/mm^3) >1.2× ULN0010110
Eosinophils (Abs) (10^3/mm^3) >1.2x ULN2311132
Monocytes (Abs) (10^3/mm^3) >1.2× ULN2202112
Activated PTT (second) >1.1× ULN1010000
PT (second) >1.1× ULN1211000
Prothrombin INR >1.1× ULN1211000
SecondaryNumber of Participants With Laboratory Test Abnormalities-clinical Chemistry (Induction Period)

The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of serum chemistry test parameters were as follows: blood urea nitrogen, creatinine, cystatin C, glucose, calcium, sodium, potassium, gamma glutamyl transferase, chloride, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, direct bilirubin, alkaline phosphatase, uric acid, albumin, total protein, creatine kinase (CK), total cholesterol, triglycerides, high-density lipoproteins (HDL), and low-density lipoprotein (LDL)

Time frame:
From Day 1 up to Week 8
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities-clinical Chemistry (Induction Period)
ParticipantsPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Bilirubin (mg/dL) >1.5x ULN0101221
Direct Bilirubin (mg/dL) >1.5x ULN0000000
Indirect Bilirubin (mg/dL) >1.5x ULN0000000
AST (U/L) >3.0x ULN0000000
ALT (U/L) >3.0x ULN0000200
Gamma Glutamyl Transferase (U/L) >3.0x ULN0000000
Alkaline Phosphatase (U/L) >3.0x ULN0100000
Protein (g/dL) <0.8x LLN0000000
Protein (g/dL) >1.2x ULN0000000
Albumin (g/dL) <0.8x LLN0000000
Albumin (g/dL) >1.2x ULN0000000
Urea Nitrogen (mg/dL) >1.3x ULN0000000
Creatinine (mg/dL) >1.3x ULN0000010
Urate (mg/dL) >1.2x ULN0010000
HDL Cholesterol (mg/dL) <0.8x LLN0000000
LDL Cholesterol (mg/dL) >1.2x ULN0010001
Triglycerides (mg/dL) >1.3x ULN1113125
Sodium(Meq/L) <0.95x LLN0000000
Sodium(Meq/L) >1.05x ULN0000000
Potassium (Meq/L) <0.9x LLN0000000
Potassium (Meq/L) >1.1x ULN0010000
Chloride (Meq/L) <0.9x LLN0000000
Chloride (Meq/L) >1.1x ULN0000000
Calcium (mg/dL) <0.9x LLN0000000
Calcium (mg/dL) >1.1x ULN0000000
Glucose (mg/dL) <0.6x LLN0000000
Glucose (mg/dL) >1.5x ULN0121102
Hemoglobin A1C (%) >1.3x ULN0000000
CK (U/L) >2.0x ULN2023236
Cholesterol (mg/dl) >1.3x ULN0010010
SecondaryNumber of Participants With Laboratory Test Abnormalities- Urinalysis (Induction Period)

The number of participants with a laboratory abnormality meeting specified criteria while on study treatment or during lag time are reported here. Baseline is defined as the last measurement prior to receiving study treatment. The list of urinalysis test parameters were as follows:pH, glucose (qual), protein (qual), blood (qual), ketones, nitrites, leukocyte esterase, microscopy, and spot urine albumin/creatinine ratio. The criteria of laboratory abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.

Time frame:
From Day 1 up to Week 8
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities- Urinalysis (Induction Period)
ParticipantsPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
pH (scalar) <4.50000000
pH (scalar) >80000000
Urine glucose (no unit) ≥10141011
Ketones (no unit) ≥11411744
Urine protein(no unit) ≥10201120
Urine hemoglobin(no unit) ≥12444584
Nitrite (no unit) ≥11121201
Leukocyte esterase (no unit) ≥13114107814
Urine erythrocytes (/HPF) ≥200011000
Urine leukocytes (/HPF) ≥201214313
Granular casts (/LPF) >11001000
Hyaline casts (/LPF) >13224421
WBC casts (/LPF) >10010000
Bacteria (no unit) >200000000
SecondaryNumber of Participants With Abnormal Vital Signs Data (Induction Period)

The vital signs data included the single sitting blood pressure, pulse rate and temperature. The criteria of vital sign abnormality are indicated below.

Time frame:
From screening to Week 8
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Vital Signs Data (Induction Period)
ParticipantsPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Sitting Systolic Blood Pressure Value <90 mmHg0110300
Sitting Systolic Blood Pressure Change ≥30 mmHg Increase0130003
Sitting Systolic Blood Pressure Change ≥30 mmHg Decrease0100010
Sitting Diastolic Blood Pressure Value <50 mmHg0010000
Sitting Diastolic Blood Pressure Change ≥20 mmHg Increase0230215
Sitting Diastolic Blood Pressure Change ≥20 mmHg Decrease0442212
Sitting Pulse Rate Value <40 bpm0000000
Sitting Pulse Rate Value >120 bpm0100000
SecondaryNumber of Participants With Abnormal Electrocardiogram (ECG) Findings (Induction Period)

The number of participants with abnormal ECG findings during the induction period (from Day 1 to Week 8) are reported below. The criteria of test abnormality is defined as one of the following conditions was met: 1)associated with accompanying symptoms;2)Test result requires additional diagnostic testing or medical/surgical intervention;3)Test result leads to a change in study dosing (outside of any protocol specified dose adjustments) or discontinuation from the study, significant additional concomitant drug treatment, or other therapy;4)Test result is considered to be an AE by the investigator or sponsor.

Time frame:
From screening to Week 8
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings (Induction Period)
ParticipantsPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
abnormal, not clinical significant (at screening)28649108
abnormal, clinical significant (at screening)0000000
abnormal, not clinical significant (at Week 8)2784543
abnormal, clinical significant (at Week 8)0001000
SecondaryNumber of Participants With Serious Infections (Induction Period)

Serious infections was defined as any infection (for example, viral, bacterial, and fungal) requiring hospitalization or parenteral antimicrobials including Listeria encephalitis, Pneumonia, Viral infection.

Time frame:
From Day 1 up to Week 8
Reported as:
Count of participants · Participants
Number of Participants With Serious Infections (Induction Period)
ParticipantsPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Listeria encephalitis0001000
Pneumonia0100000
Viral infection0100000
SecondaryPercentage of Participants Achieving Remission Based on Total Mayo Score at Week 8 (Induction Period)

The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Clinical remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0.

Time frame:
Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Remission Based on Total Mayo Score at Week 8 (Induction Period)
Percentage of participantsPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Percentage of Participants Achieving Remission Based on Total Mayo Score at Week 8 (Induction Period)0 (0.0 to 11.0)9.8 (4.8 to 19.1)28.6 (19.0 to 40.4)34.0 (24.0 to 45.4)8.3 (3.7 to 16.8)23.4 (14.8 to 34.5)23.4 (14.8 to 34.5)
Statistical analysis
  • Placebo (Induction) vs PF-06651600 20 mg (Induction) · Chan and Zhang method · p = 0.0626 · Mean difference (final values): 9.8 · 90% CI -1.0 to 19.5
  • Placebo (Induction) vs PF-06651600 70 mg (Induction) · Chan and Zhang method · p = 0.0027 · Mean difference (final values): 28.6 · 90% CI 13.9 to 41.0
  • Placebo (Induction) vs PF-06651600 200 mg (Induction) · Chan and Zhang Method · p = 0.0010 · Mean difference (final values): 34.0 · 90% CI 20.2 to 46.5
  • Placebo (Induction) vs PF-06700841 10 mg (Induction) · Chan and Zhang method · p = 0.0774 · Mean difference (final values): 8.3 · 90% CI -4.0 to 18.1
  • Placebo (Induction) vs PF-06700841 30 mg (Induction) · Chan and Zhang method · p = 0.0055 · Mean difference (final values): 23.4 · 90% CI 8.2 to 35.8
  • Placebo (Induction) vs PF-06700841 60 mg (Induction) · Chan and Zhang method · p = 0.0055 · Mean difference (final values): 23.4 · 90% CI 8.2 to 35.8
SecondaryPercentage of Participants Achieving Improvement in Endoscopic Appearance Based on Total Mayo Score at Week 8 (Induction Period)

The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Improvement in endoscopic subscore appearance was defined at Mayo endoscopic subscore of ≤1.

Time frame:
Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Improvement in Endoscopic Appearance Based on Total Mayo Score at Week 8 (Induction Period)
Percentage of participantsPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Percentage of Participants Achieving Improvement in Endoscopic Appearance Based on Total Mayo Score at Week 8 (Induction Period)0 (0.0 to 11.0)21.6 (13.5 to 33.1)34.7 (24.4 to 46.4)42.0 (30.3 to 54.6)20.8 (11.8 to 31.5)31.9 (20.8 to 44.4)29.8 (19.9 to 42.3)
Statistical analysis
  • Placebo (Induction) vs PF-06651600 20 mg (Induction) · Chan and Zhang method · p = 0.0111 · Mean difference (final values): 21.6 · 90% CI 5.6 to 33.2
  • Placebo (Induction) vs PF-06651600 70 mg (Induction) · Chan and Zhang method · p = 0.0006 · Mean difference (final values): 34.7 · 90% CI 20.2 to 47.4
  • Placebo (Induction) vs PF-06651600 200 mg (Induction) · Chan and Zhang Method · p = 0.0001 · Mean difference (final values): 42.0 · 90% CI 29.5 to 54.6
  • Placebo (Induction) vs PF-06700841 10 mg (Induction) · Chan and Zhang method · p = 0.0101 · Mean difference (final values): 20.8 · 90% CI 5.6 to 33.0
  • Placebo (Induction) vs PF-06700841 30 mg (Induction) · Chan and Zhang method · p = 0.0014 · Mean difference (final values): 31.9 · 90% CI 17.0 to 44.8
  • Placebo (Induction) vs PF-06700841 60 mg (Induction) · Chan and Zhang method · p = 0.0015 · Mean difference (final values): 29.8 · 90% CI 17.0 to 42.6
SecondaryPercentage of Participants Achieving Clinical Response Based on Total Mayo Score at Week 8 (Induction Period)

The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Clinical response was defined as decrease from baseline in total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the subscore for rectal bleeding of at least 1 point or absolute subscore for rectal bleeding of 0 or 1.

Time frame:
Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Response Based on Total Mayo Score at Week 8 (Induction Period)
Percentage of participantsPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Percentage of Participants Achieving Clinical Response Based on Total Mayo Score at Week 8 (Induction Period)24.0 (11.0 to 41.7)41.2 (29.9 to 53.6)69.4 (57.6 to 80.1)68.0 (56.6 to 78.8)41.7 (29.6 to 54.5)53.2 (40.3 to 65.5)61.7 (48.7 to 72.9)
Statistical analysis
  • Placebo (Induction) vs PF-06651600 20 mg (Induction) · Chan and Zhang method · p = 0.0788 · Mean difference (final values): 17.2 · 90% CI -3.4 to 34.4
  • Placebo (Induction) vs PF-06651600 70 mg (Induction) · Chan and Zhang method · p = 0.0002 · Mean difference (final values): 45.4 · 90% CI 23.6 to 62.1
  • Placebo (Induction) vs PF-06651600 200 mg (Induction) · Chan and Zhang Method · p = 0.0003 · Mean difference (final values): 44.0 · 90% CI 23.5 to 60.5
  • Placebo (Induction) vs PF-06700841 10 mg (Induction) · Chan and Zhang method · p = 0.0773 · Mean difference (final values): 17.7 · 90% CI -4.0 to 35.1
  • Placebo (Induction) vs PF-06700841 30 mg (Induction) · Chan and Zhang method · p = 0.0136 · Mean difference (final values): 29.2 · 90% CI 5.6 to 47.0
  • Placebo (Induction) vs PF-06700841 60 mg (Induction) · Chan and Zhang method · p = 0.0015 · Mean difference (final values): 37.7 · 90% CI 13.9 to 54.7
SecondaryPercentage of Participants Achieving Endoscopic Remission Based on Total Mayo Score at Week 8 (Induction Period)

The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Endoscopic remission was defined as endoscopic subscore of 0.

Time frame:
Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Endoscopic Remission Based on Total Mayo Score at Week 8 (Induction Period)
Percentage of participantsPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Percentage of Participants Achieving Endoscopic Remission Based on Total Mayo Score at Week 8 (Induction Period)0 (0.0 to 11.0)3.9 (1.0 to 11.0)8.2 (3.6 to 16.5)12.0 (5.4 to 21.2)2.1 (0.2 to 8.6)17.0 (8.8 to 28.3)8.5 (3.8 to 17.2)
Statistical analysis
  • Placebo (Induction) vs PF-06651600 20 mg (Induction) · Chan and Zhang method · p = 0.2259 · Mean difference (final values): 3.9 · 90% CI -6.5 to 11.8
  • Placebo (Induction) vs PF-06651600 70 mg (Induction) · Chan and Zhang method · p = 0.0820 · Mean difference (final values): 8.2 · 90% CI -3.8 to 17.7
  • Placebo (Induction) vs PF-06651600 200 mg (Induction) · Chan and Zhang Method · p = 0.0649 · Mean difference (final values): 12.0 · 90% CI -0.7 to 22.3
  • Placebo (Induction) vs PF-06700841 10 mg (Induction) · Chan and Zhang method · p = 0.3777 · Mean difference (final values): 2.1 · 90% CI -8.6 to 9.7
  • Placebo (Induction) vs PF-06700841 30 mg (Induction) · Chan and Zhang method · p = 0.0212 · Mean difference (final values): 17.0 · 90% CI 2.9 to 28.6
  • Placebo (Induction) vs PF-06700841 60 mg (Induction) · Chan and Zhang method · p = 0.0742 · Mean difference (final values): 8.5 · 90% CI -4.2 to 18.4
SecondaryPercentage of Participants Achieving Symptomatic Remission Based on Total Mayo Score at Week 8 (Induction Period)

The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Symptomatic remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point, and both rectal bleeding and stool frequency subscores of 0.

Time frame:
Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Symptomatic Remission Based on Total Mayo Score at Week 8 (Induction Period)
Percentage of participantsPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Percentage of Participants Achieving Symptomatic Remission Based on Total Mayo Score at Week 8 (Induction Period)0 (0.0 to 11.0)7.8 (3.5 to 15.9)16.3 (8.4 to 27.1)26.0 (16.2 to 37.6)6.3 (2.3 to 15.1)14.9 (8.0 to 25.1)14.9 (8.0 to 25.1)
Statistical analysis
  • Placebo (Induction) vs PF-06651600 20 mg (Induction) · Chan and Zhang method · p = 0.0872 · Mean difference (final values): 7.8 · 90% CI -3.4 to 17.1
  • Placebo (Induction) vs PF-06651600 70 mg (Induction) · Chan and Zhang method · p = 0.0254 · Mean difference (final values): 16.3 · 90% CI 3.0 to 27.5
  • Placebo (Induction) vs PF-06651600 200 mg (Induction) · Chan and Zhang Method · p = 0.0034 · Mean difference (final values): 26.0 · 90% CI 11.0 to 38.1
  • Placebo (Induction) vs PF-06700841 10 mg (Induction) · Chan and Zhang method · p = 0.1565 · Mean difference (final values): 6.3 · 90% CI -4.5 to 15.4
  • Placebo (Induction) vs PF-06700841 30 mg (Induction) · Chan and Zhang method · p = 0.0288 · Mean difference (final values): 14.9 · 90% CI 1.7 to 26.2
  • Placebo (Induction) vs PF-06700841 60 mg (Induction) · Chan and Zhang method · p = 0.0288 · Mean difference (final values): 14.9 · 90% CI 1.7 to 26.2
SecondaryPercentage of Participants Achieving Deep Remission Based on Total Mayo Score at Week 8 (Induction Period)

The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Deep remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a zero on both endoscopic and rectal bleeding subscore.

Time frame:
Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Deep Remission Based on Total Mayo Score at Week 8 (Induction Period)
Percentage of participantsPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Percentage of Participants Achieving Deep Remission Based on Total Mayo Score at Week 8 (Induction Period)0 (0.0 to 11.0)3.9 (1.0 to 11.0)8.2 (3.6 to 16.5)12.0 (5.4 to 21.2)0 (0.0 to 5.6)14.9 (8.0 to 25.1)6.4 (2.4 to 15.4)
Statistical analysis
  • Placebo (Induction) vs PF-06651600 20 mg (Induction) · Chan and Zhang method · p = 0.2259 · Mean difference (final values): 3.9 · 90% CI -6.5 to 11.8
  • Placebo (Induction) vs PF-06651600 70 mg (Induction) · Chan and Zhang method · p = 0.0820 · Mean difference (final values): 8.2 · 90% CI -3.8 to 17.7
  • Placebo (Induction) vs PF-06651600 200 mg (Induction) · Chan and Zhang Method · p = 0.0649 · Mean difference (final values): 12.0 · 90% CI -0.7 to 22.3
  • Placebo (Induction) vs PF-06700841 10 mg (Induction) · Chan and Zhang method · p = 1.0000 · Mean difference (final values): 0.0 · 90% CI -11.3 to 6.1
  • Placebo (Induction) vs PF-06700841 30 mg (Induction) · Chan and Zhang method · p = 0.0288 · Mean difference (final values): 14.9 · 90% CI 1.7 to 26.2
  • Placebo (Induction) vs PF-06700841 60 mg (Induction) · Chan and Zhang method · p = 0.1593 · Mean difference (final values): 6.4 · 90% CI -4.4 to 15.7
SecondaryPartial Mayo Score and Change From Baseline at Weeks 2, 4 and 8 (Induction Period)

The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. The partial Mayo score does not incorporate the endoscopy score and the partial Mayo score ranges from 0 to 9.

Time frame:
Baseline, Weeks 2, 4 and 8
Reported as:
Least squares mean · Units on a scale
Partial Mayo Score and Change From Baseline at Weeks 2, 4 and 8 (Induction Period)
Units on a scalePlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Week 2-0.66 ± 0.37-1.65 ± 0.26-2.56 ± 0.26-3.19 ± 0.27-1.6 ± 0.27-1.64 ± 0.27-2.45 ± 0.27
Week 4-1.64 ± 0.42-2.24 ± 0.29-3.29 ± 0.30-4.24 ± 0.31-2.31 ± 0.30-2.06 ± 0.30-2.95 ± 0.30
Week 8-1.15 ± 0.43-2.54 ± 0.30-4.06 ± 0.30-4.69 ± 0.32-2.51 ± 0.30-2.71 ± 0.31-3.47 ± 0.31
SecondaryChange From Baseline in Total Mayo Score at Week 8 (Induction Period)

The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity.

Time frame:
Baseline, Week 8
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Total Mayo Score at Week 8 (Induction Period)
Units on a scalePlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Change From Baseline in Total Mayo Score at Week 8 (Induction Period)-1.14 (-2.06 to -0.22)-3.17 (-3.83 to -2.51)-5.02 (-5.68 to -4.36)-5.74 (-6.43 to -5.06)-2.93 (-3.58 to -2.29)-3.42 (-4.08 to -2.76)-4.35 (-5.00 to -3.69)
SecondaryInflammatory Bowel Disease Questionnaire (IBDQ) Domain Score and Total Score at Weeks 4 and 8 (Induction Period)

IBDQ is a psychometrically validated patient reported outcome (PRO) instrument for measuring the disease specific quality of life in participants with inflammatory bowel disease (IBD). The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life.

Time frame:
Week 4 and Week 8
Reported as:
Mean · Units on a scale
Inflammatory Bowel Disease Questionnaire (IBDQ) Domain Score and Total Score at Weeks 4 and 8 (Induction Period)
Units on a scalePlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Baseline (Bowel Systems Domain score)35.80 (32.48 to 39.12)34.29 (31.74 to 36.85)33.71 (31.41 to 36.01)34.84 (32.66 to 37.01)34.17 (32.13 to 36.21)32.38 (29.99 to 34.77)33.38 (31.36 to 35.40)
Week 4 (Bowel Systems Domain score)44.87 (40.65 to 49.09)46.98 (44.05 to 49.91)51.00 (48.45 to 53.55)53.80 (50.83 to 56.76)44.93 (42.00 to 47.86)46.84 (43.56 to 50.12)50.64 (47.66 to 53.61)
Week 8 (Bowel Systems Domain score)44.68 (41.37 to 47.99)47.96 (44.68 to 51.23)54.27 (51.38 to 57.16)55.95 (53.40 to 58.50)46.87 (43.46 to 50.27)50.12 (47.12 to 53.11)53.45 (50.53 to 56.38)
Baseline (Emotion Health Domain score)43.76 (38.81 to 48.71)42.76 (39.37 to 46.16)42.90 (39.56 to 46.24)41.39 (37.88 to 44.90)42.40 (39.15 to 45.65)38.74 (35.59 to 41.90)41.43 (38.56 to 44.29)
Week 4(Emotion Health Domain score)54.74 (49.67 to 59.81)53.65 (49.92 to 57.39)59.89 (56.83 to 62.96)61.11 (57.54 to 64.68)52.43 (48.26 to 56.61)52.77 (48.99 to 56.55)57.86 (54.06 to 61.67)
Week 8(Emotion Health Domain score)52.50 (47.61 to 57.39)54.23 (50.29 to 58.17)62.73 (59.30 to 66.17)63.12 (59.28 to 66.96)54.44 (50.02 to 58.87)56.86 (53.34 to 60.38)60.89 (57.09 to 64.69)
Baseline (Systemic Systems Domain score)16.56 (14.83 to 18.29)16.12 (14.74 to 17.50)15.98 (14.67 to 17.29)15.41 (14.14 to 16.68)16.30 (14.93 to 17.67)15.21 (14.06 to 16.36)16.72 (15.40 to 18.05)
Week 4(Systemic Systems Domain score)20.87 (18.56 to 23.18)21.70 (20.34 to 23.05)23.74 (22.44 to 25.05)23.66 (22.08 to 25.23)20.70 (19.03 to 22.36)20.77 (19.24 to 22.30)23.61 (21.89 to 25.34)
Week 8(Systemic Systems Domain score)20.82 (19.11 to 22.53)21.85 (20.20 to 23.50)24.40 (22.91 to 25.89)25.51 (24.17 to 26.86)21.40 (19.56 to 23.24)23.07 (21.50 to 24.64)24.48 (22.72 to 26.24)
Baseline (Social Function Domain score)16.88 (14.41 to 19.35)17.25 (15.43 to 19.08)16.59 (14.70 to 18.48)17.31 (15.73 to 18.88)17.30 (15.69 to 18.91)14.91 (13.28 to 16.55)16.64 (15.06 to 18.22)
Week 4 (Social Function Domain score)22.57 (19.80 to 25.33)22.41 (20.57 to 24.25)26.21 (24.73 to 27.70)28.20 (26.42 to 29.99)22.83 (20.78 to 24.87)23.02 (20.82 to 25.23)24.86 (22.55 to 27.17)
Week 8 (Social Function Domain score)21.91 (19.27 to 24.55)23.45 (21.45 to 25.44)27.02 (25.06 to 28.99)29.80 (28.14 to 31.47)24.36 (22.11 to 26.60)25.12 (22.88 to 27.35)26.57 (24.50 to 28.63)
Baseline (Total IBDQ score)113.00 (101.49 to 124.51)110.43 (101.85 to 119.01)109.18 (101.30 to 117.07)108.94 (101.20 to 116.68)110.17 (102.94 to 117.40)101.26 (93.85 to 108.66)108.17 (101.13 to 115.21)
Week 4 (Total IBDQ score)143.04 (129.90 to 156.19)144.74 (135.60 to 153.88)160.85 (153.50 to 168.20)166.77 (157.55 to 176.00)140.89 (130.88 to 150.90)143.41 (133.62 to 153.20)156.98 (146.69 to 167.27)
Week 8 (Total IBDQ score)139.91 (128.72 to 151.10)147.49 (137.17 to 157.80)168.42 (159.53 to 177.31)174.39 (165.67 to 183.11)147.07 (135.79 to 158.35)155.16 (145.67 to 164.65)165.39 (155.29 to 175.49)
SecondaryChange From Baseline in IBDQ Total Score at Weeks 4 and 8 (Induction Period)

IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life. Baseline value is defined as the last non-missing measurement collected prior to or on Day 1.

Time frame:
Baseline, Weeks 4 and 8
Reported as:
Least squares mean · Units on a scale
Change From Baseline in IBDQ Total Score at Weeks 4 and 8 (Induction Period)
Units on a scalePlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Week 430.30 ± 6.5133.71 ± 4.6051.12 ± 4.6157.01 ± 4.7828.45 ± 4.6837.94 ± 4.7249.79 ± 4.73
Week 824.23 ± 7.4037.91 ± 5.1559.20 ± 5.2362.17 ± 5.4736.60 ± 5.2948.81 ± 5.3356.39 ± 5.33
SecondaryPercentage of Participants With IBDQ Total Score Greater Than or Equal to 170 at Weeks 4 and 8 (Induction Period)

IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life.

Time frame:
Week 4 and Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants With IBDQ Total Score Greater Than or Equal to 170 at Weeks 4 and 8 (Induction Period)
Percentage of participantsPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Week 424.0 (11.0 to 41.7)21.6 (13.5 to 33.1)40.8 (28.9 to 53.6)46.0 (34.2 to 58.5)27.1 (16.8 to 39.4)27.7 (17.2 to 40.3)38.3 (27.1 to 51.3)
Week 820.0 (10.1 to 36.2)29.4 (19.1 to 40.6)57.1 (44.4 to 69.2)44.0 (33.0 to 56.6)31.3 (20.4 to 43.4)40.4 (28.3 to 53.5)51.1 (38.9 to 62.8)
SecondaryPercentage of Participants With Greater Than or Equal to 16 Points Increase in IBDQ Total Score From Baseline at Weeks 4 and 8 (Induction Period)

IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life.

Time frame:
Baseline, Week 4 and 8
Reported as:
Number · Percentage of participants
Percentage of Participants With Greater Than or Equal to 16 Points Increase in IBDQ Total Score From Baseline at Weeks 4 and 8 (Induction Period)
Percentage of participantsPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Week 448.0 (30.7 to 64.0)60.8 (48.4 to 72.3)83.7 (72.9 to 91.6)80.0 (69.7 to 88.7)64.6 (52.5 to 75.3)78.7 (67.8 to 88.0)72.3 (59.7 to 82.8)
Week 856.0 (38.9 to 73.0)54.9 (42.5 to 66.9)79.6 (69.2 to 88.5)70.0 (58.5 to 80.5)62.5 (50.0 to 73.6)80.9 (69.7 to 88.8)78.7 (67.8 to 88.0)
SecondaryPercentage of Participants With Improvement in IBDQ Bowel Symptom Domain at Weeks 4 and 8 (Induction Period)

IBDQ is a psychometrically validated PRO instrument for measuring the disease specific quality of life in participants with IBD. The IBDQ is comprised of 32 items, which are grouped into 4 dimensions: bowel function, emotional status, systemic symptoms and social function. The 4 domains are scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35.; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranges from 32 to 224. For the total score and each domain, a higher score indicates better quality of life. The improvement in IBDQ bowel symptom domain was defined as an increase of ≥1.2 points from baseline in average score among bowel symptoms domain (items 1, 5, 9, 13, 17, 20, 22, 24, 26, 29).

Time frame:
Week 4 and Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement in IBDQ Bowel Symptom Domain at Weeks 4 and 8 (Induction Period)
Percentage of participantsPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Week 420.0 (10.1 to 36.2)51.0 (38.7 to 63.2)65.3 (53.6 to 75.6)64.0 (42.6 to 75.1)37.5 (26.4 to 50.0)53.2 (40.3 to 65.5)57.5 (44.4 to 69.7)
Week 824.0 (11.0 to 41.7)47.1 (35.0 to 59.4)69.4 (57.6 to 80.1)62.0 (50.0 to 73.5)50.0 (37.6 to 62.4)63.8 (51.3 to 74.9)66.0 (53.5 to 77.3)
SecondaryChange From Baseline in Short Form 36 Version 2 (SF-36v2) Acute Mental Component Summary (MCS) Score and Physical Component Summary (PCS) Score at Weeks 4 and 8 (Induction Period)

The SF-36 version 2 (Acute version) is a 36-item generic health status measure. It measures 8 general health concepts or domains: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH). These 8 domains can also be summarized as physical and mental component scores. The summary component scores, Physical Component Summary (PCS) and Mental Component Summary (MCS), are based on a normalized sum of the 8 scale scores PF, RP, BP, GH, VT, SF, RE, and MH . All domains and summary components are scored such that a higher score indicates a higher functioning or health level. The minimum and maximum scores of the PCS Score are 6.1 and 79.7, respectively. The minimum and maximum scores of the MCS Score are -3.8 and 78.7, respectively.

Time frame:
Week 4 and Week 8
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Short Form 36 Version 2 (SF-36v2) Acute Mental Component Summary (MCS) Score and Physical Component Summary (PCS) Score at Weeks 4 and 8 (Induction Period)
Units on a scalePlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
Week 4 (PCS)4.69 (2.59 to 6.80)5.90 (4.41 to 7.39)6.36 (4.88 to 7.85)9.21 (7.67 to 10.76)5.67 (4.16 to 7.19)5.85 (4.31 to 7.38)6.40 (4.87 to 7.93)
Week 8 (PCS)5.37 (2.96 to 7.77)5.85 (4.19 to 7.52)8.66 (6.97 to 10.35)10.86 (9.08 to 12.64)6.29 (4.57 to 8.02)8.21 (6.47 to 9.95)8.55 (6.83 to 10.27)
Week 4(MCS)7.83 (4.59 to 11.06)4.95 (2.67 to 7.23)7.79 (5.50 to 10.07)8.81 (6.43 to 11.18)2.44 (0.13 to 4.74)7.46 (5.11 to 9.82)9.28 (6.93 to 11.62)
Week 8(MCS)4.24 (0.69 to 7.78)5.18 (2.72 to 7.64)9.72 (7.22 to 12.22)9.41 (6.79 to 12.03)5.22 (2.70 to 7.75)8.04 (5.48 to 10.61)10.01 (7.47 to 12.55)
SecondaryChange From Baseline in Euro Quality of Life Questionnaire 5 Dimensions 3 Levels (EQ-5D 3L) Utility Score and EQ-5D Visual Analog Scale (VAS) at Weeks 4 and 8 (Induction Period)

For EQ-5D 3L, participant rated questionnaire to assess generic health status in two parts: single utility score and visual analog scale. For utility score, participants rated their current health state on 5 dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression with each dimension having three levels of function: 1 indicates no problem; 2 indicates some problem; 3 indicates extreme problem. Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score was transformed and results in a total score range of 0.05 to 1.00; higher scores indicating a better health state. The EQ-5D VAS records the respondent's self rated health on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state).

Time frame:
Week 4 and Week 8
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Euro Quality of Life Questionnaire 5 Dimensions 3 Levels (EQ-5D 3L) Utility Score and EQ-5D Visual Analog Scale (VAS) at Weeks 4 and 8 (Induction Period)
Units on a scalePlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)
EQ-5D 3L Utility Score (Week 4)0.11 (0.06 to 0.16)0.07 (0.04 to 0.11)0.12 (0.09 to 0.15)0.13 (0.10 to 0.17)0.07 (0.03 to 0.10)0.11 (0.08 to 0.14)0.12 (0.09 to 0.15)
EQ-5D 3L Utility Score (Week 8)0.08 (0.03 to 0.13)0.08 (0.05 to 0.12)0.15 (0.11 to 0.18)0.15 (0.12 to 0.19)0.09 (0.05 to 0.13)0.13 (0.10 to 0.17)0.14 (0.11 to 0.18)
EQ-5D VAS Score (Week 4)8.41 (2.18 to 14.63)13.60 (9.20 to 18.00)16.35 (11.96 to 20.74)17.45 (12.88 to 22.02)10.48 (6.04 to 14.92)12.24 (7.72 to 16.77)14.44 (9.90 to 18.97)
EQ-5D VAS Score (Week 8)13.17 (6.48 to 19.85)13.11 (8.48 to 17.74)18.88 (14.17 to 23.60)22.54 (17.60 to 27.49)10.35 (5.58 to 15.12)17.11 (12.28 to 21.94)20.01 (15.21 to 24.81)
SecondaryTotal Mayo Score at Week 32 (Chronic Period)

The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity.

Time frame:
Week 32
Reported as:
Least squares mean · Units on a scale
Total Mayo Score at Week 32 (Chronic Period)
Units on a scalePlacebo -> PF-06651600 50 mgPF-06651600 20 mg -> PF-06651600 50 mgPF-06651600 70 mg -> PF-06651600 50 mgPF-06651600 200 mg -> PF-06651600 50 mgPlacebo -> PF-06700841 30 mgPF-06700841 10 mg -> PF-06700841 30 mgPF-06700841 60 mg -> PF-06700841 30 mgPF-06700841 30 mg -> PF-06700841 30 mg
Total Mayo Score at Week 32 (Chronic Period)4.13 (2.82 to 5.44)3.47 (2.75 to 4.19)3.46 (2.77 to 4.16)2.89 (2.18 to 3.60)4.62 (2.62 to 6.61)3.81 (2.94 to 4.68)3.63 (2.67 to 4.59)3.86 (2.98 to 4.75)
SecondaryPercentage of Participants Achieving Remission Based on Total Mayo Score at Week 32 (Chronic Period)

The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Clinical remission was defined as total Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0.

Time frame:
Week 32
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Remission Based on Total Mayo Score at Week 32 (Chronic Period)
Percentage of participantsPlacebo -> PF-06651600 50 mgPF-06651600 20 mg -> PF-06651600 50 mgPF-06651600 70 mg -> PF-06651600 50 mgPF-06651600 200 mg -> PF-06651600 50 mgPlacebo -> PF-06700841 30 mgPF-06700841 10 mg -> PF-06700841 30 mgPF-06700841 60 mg -> PF-06700841 30 mgPF-06700841 30 mg -> PF-06700841 30 mg
Percentage of Participants Achieving Remission Based on Total Mayo Score at Week 32 (Chronic Period)16.7 (4.5 to 39.8)23.9 (15.1 to 35.0)28.6 (17.4 to 41.0)34.1 (22.3 to 46.5)18.2 (4.9 to 43.6)21.4 (12.6 to 34.2)26.8 (17.1 to 39.8)26.8 (17.1 to 39.8)
SecondaryPercentage of Participants Achieving Improvement in Endoscopic Appearance Based on Mayo Score at Week 32 (Chronic Period)

The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity. Improvement in endoscopic appearance was defined at Mayo endoscopic subscore of ≤1.

Time frame:
Week 32
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Improvement in Endoscopic Appearance Based on Mayo Score at Week 32 (Chronic Period)
Percentage of participantsPlacebo -> PF-06651600 50 mgPF-06651600 20 mg -> PF-06651600 50 mgPF-06651600 70 mg -> PF-06651600 50 mgPF-06651600 200 mg -> PF-06651600 50 mgPlacebo -> PF-06700841 30 mgPF-06700841 10 mg -> PF-06700841 30 mgPF-06700841 60 mg -> PF-06700841 30 mgPF-06700841 30 mg -> PF-06700841 30 mg
Percentage of Participants Achieving Improvement in Endoscopic Appearance Based on Mayo Score at Week 32 (Chronic Period)33.3 (15.4 to 60.2)26.1 (15.8 to 37.7)40.5 (27.7 to 54.3)34.1 (22.3 to 46.5)18.2 (4.9 to 43.6)31.0 (19.4 to 43.3)34.1 (23.0 to 46.9)36.6 (24.6 to 50.0)
Other pre-specifiedChange From Baseline in Total Mayo Score at Week 32 (Chronic Period)

The Mayo Score is a tool designed to measure disease activity for ulcerative colitis. The Mayo scoring system ranges from 0 to 12 points and consists of 4 subscores, which are stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscore graded 0 to 3 with the higher score indicating more severe disease activity.

Time frame:
Week 32
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Total Mayo Score at Week 32 (Chronic Period)
Units on a scalePlacebo -> PF-06651600 50 mgPF-06651600 20 mg -> PF-06651600 50 mgPF-06651600 70 mg -> PF-06651600 50 mgPF-06651600 200 mg -> PF-06651600 50 mgPlacebo -> PF-06700841 30 mgPF-06700841 10 mg -> PF-06700841 30 mgPF-06700841 60 mg -> PF-06700841 30 mgPF-06700841 30 mg -> PF-06700841 30 mg
Change From Baseline in Total Mayo Score at Week 32 (Chronic Period)-4.88 (-6.19 to -3.57)-5.54 (-6.26 to -4.82)-5.55 (-6.24 to -4.85)-6.12 (-6.83 to -5.41)-4.45 (-6.45 to -2.45)-5.26 (-6.12 to -4.39)-5.21 (-6.09 to -4.32)-5.44 (-6.39 to -4.48)

Adverse events

Collected over From the time the participants took at least 1 dose of study treatment up to 28 days after the last treatment administration. (approximately 36 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Induction)0/25 (0%)0/25 (0%)4/25 (16%)
PF-06651600 20 mg (Induction)1/51 (2%)3/51 (5.9%)8/51 (15.7%)
PF-06651600 70 mg (Induction)0/49 (0%)0/49 (0%)6/49 (12.2%)
PF-06651600 200 mg (Induction)0/50 (0%)3/50 (6%)5/50 (10%)
PF-06700841 10 mg (Induction)0/48 (0%)1/48 (2.1%)2/48 (4.2%)
PF-06700841 30 mg (Induction)0/47 (0%)3/47 (6.4%)11/47 (23.4%)
PF-06700841 60 mg (Induction)0/47 (0%)1/47 (2.1%)9/47 (19.1%)
PF-06651600 200 mg -> PF-06651600 50 mg0/35 (0%)3/35 (8.6%)9/35 (25.7%)
PF-06651600 70 mg -> PF-06651600 50 mg0/36 (0%)1/36 (2.8%)21/36 (58.3%)
PF-06651600 20 mg -> PF-06651600 50 mg0/39 (0%)1/39 (2.6%)11/39 (28.2%)
Placebo -> PF-06651600 50 mg0/10 (0%)0/10 (0%)8/10 (80%)
PF-06700841 60 mg -> PF-06700841 30 mg0/38 (0%)2/38 (5.3%)15/38 (39.5%)
PF-06700841 30 mg -> PF-06700841 30 mg0/37 (0%)4/37 (10.8%)15/37 (40.5%)
PF-06700841 10 mg -> PF-06700841 30 mg0/39 (0%)2/39 (5.1%)20/39 (51.3%)
Placebo -> PF-06700841 30 mg0/9 (0%)0/9 (0%)4/9 (44.4%)
Pooling Placebo During Chronic0/37 (0%)0/37 (0%)15/37 (40.5%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)PF-06651600 200 mg -> PF-06651600 50 mgPF-06651600 70 mg -> PF-06651600 50 mgPF-06651600 20 mg -> PF-06651600 50 mgPlacebo -> PF-06651600 50 mgPF-06700841 60 mg -> PF-06700841 30 mgPF-06700841 30 mg -> PF-06700841 30 mgPF-06700841 10 mg -> PF-06700841 30 mgPlacebo -> PF-06700841 30 mgPooling Placebo During Chronic
Colitis ulcerativeGastrointestinal disorders0/251/510/491/501/480/470/470/351/361/390/101/382/371/390/90/37
Ankle fractureInjury, poisoning and procedural complications0/250/510/490/500/480/470/471/350/360/390/100/380/370/390/90/37
Femur fractureInjury, poisoning and procedural complications0/250/510/490/500/480/470/471/350/360/390/100/380/370/390/90/37
UrticariaSkin and subcutaneous tissue disorders0/250/510/490/500/480/470/471/350/360/390/100/380/370/390/90/37
Myocardial infarctionCardiac disorders0/251/510/490/500/480/470/470/350/360/390/100/381/370/390/90/37
Large intestine perforationGastrointestinal disorders0/250/510/490/500/480/470/470/350/360/390/100/381/370/390/90/37
Viral infectionInfections and infestations0/251/510/490/500/480/470/470/350/360/390/101/380/370/390/90/37
DehydrationMetabolism and nutrition disorders0/250/510/490/500/480/470/470/350/360/390/101/380/370/390/90/37
Acute kidney injuryRenal and urinary disorders0/250/510/490/500/480/470/470/350/360/390/101/380/370/390/90/37
COVID-19 pneumoniaInfections and infestations0/250/510/490/500/480/470/470/350/360/390/100/380/371/390/90/37
Most frequent other events
Showing 10 of 41
Most frequent other events
EventPlacebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)PF-06651600 200 mg -> PF-06651600 50 mgPF-06651600 70 mg -> PF-06651600 50 mgPF-06651600 20 mg -> PF-06651600 50 mgPlacebo -> PF-06651600 50 mgPF-06700841 60 mg -> PF-06700841 30 mgPF-06700841 30 mg -> PF-06700841 30 mgPF-06700841 10 mg -> PF-06700841 30 mgPlacebo -> PF-06700841 30 mgPooling Placebo During Chronic
Colitis ulcerativeGastrointestinal disorders0/250/510/490/500/480/470/474/355/364/393/102/382/376/391/98/37
HeadacheNervous system disorders2/253/513/490/501/484/470/470/350/360/392/101/381/372/390/91/37
Deafness unilateralEar and labyrinth disorders0/250/510/490/500/480/470/470/350/361/392/100/380/370/390/90/37
DiarrhoeaGastrointestinal disorders0/250/510/490/500/480/470/471/352/360/392/101/382/370/390/90/37
OsteoarthritisMusculoskeletal and connective tissue disorders0/250/510/490/500/480/470/470/350/360/392/100/380/371/390/90/37
HypertensionVascular disorders0/250/510/490/500/480/470/470/354/360/392/100/381/372/390/90/37
NasopharyngitisInfections and infestations0/252/510/491/500/485/473/471/351/360/390/104/385/372/391/94/37
AnaemiaBlood and lymphatic system disorders1/251/512/494/501/481/474/471/350/360/391/101/380/372/391/92/37
PyrexiaGeneral disorders0/250/510/490/500/480/470/471/352/361/391/101/380/372/391/91/37
SciaticaNervous system disorders0/250/510/490/500/480/470/470/350/360/390/100/380/370/391/90/37

Baseline characteristics

All randomized participants who received at least 1 dose of PF-06651600, PF-06700841, or placebo.

Age, Continuous
Age, Continuous(years)Placebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)Total
Mean42.8 ± 15.4541.3 ± 14.0340.2 ± 13.3137.3 ± 15.6740.8 ± 13.0440.9 ± 13.0340.3 ± 12.8040.3 ± 13.79
Age, Customized
Age, Customized(Participants)Placebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)Total
18-44 years13313036312530196
45-64 years10161810162216108
>=65 years241410113
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)Total
Female11172518182422135
Male14342432302325182
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo (Induction)PF-06651600 20 mg (Induction)PF-06651600 70 mg (Induction)PF-06651600 200 mg (Induction)PF-06700841 10 mg (Induction)PF-06700841 30 mg (Induction)PF-06700841 60 mg (Induction)Total
White22464648444445295
Black or African American11210016
Asian131033011
Other (not specified)11011015
08

Study locations

189 sites
  • Dothan Surgery Center
    Dothan, Alabama 36301, United States
  • Gut P.C., dba Digestive Health Specialists of the Southeast
    Dothan, Alabama 36305, United States
  • Long Beach Clinical Trials Services Inc.
    Long Beach, California 90806, United States
  • Southern California Research Institute Medical Group/West Gastroenterology Medical Group/Airport En-
    Los Angeles, California 90045, United States
  • Clinical Application Laboratories, INC.
    San Diego, California 92103, United States
  • San Diego Endoscopy Center
    San Diego, California 92103, United States
  • Medical Associates Research Group
    San Diego, California 92123, United States
  • Front Range Endoscopy Center
    Colorado Springs, Colorado 80903, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80907, United States
  • Bristol Hospital
    Bristol, Connecticut 06010, United States
  • Connecticut Clinical Research Institute
    Bristol, Connecticut 06010, United States
  • Central Connecticut Endoscopy Center
    Plainville, Connecticut 06062, United States
  • West Coast Endoscopy Center
    Clearwater, Florida 33756, United States
  • University of Miami Hospital and Clinics
    Miami, Florida 33136, United States
  • University of Miami Hospital
    Miami, Florida 33136, United States
  • Millenia Surgery Center
    Orlando, Florida 32811, United States
  • HMD Research LLC
    Orlando, Florida 32819, United States
  • Orlando Gastroenterology, PA
    Orlando, Florida 32835, United States
  • Southwest Gastroenterology
    Oak Lawn, Illinois 60453, United States
  • Chevy Chase Endoscopy Center
    Chevy Chase, Maryland 20815, United States
  • Feldman ENT
    Chevy Chase, Maryland 20815, United States
  • MGG Group Co. Inc., Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Cascades Endoscopy Center
    Columbia, Maryland 21045, United States
  • Gastro Center of Maryland
    Columbia, Maryland 21045, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Brigham and Women's Hospital
    Chestnut Hill, Massachusetts 02467, United States
  • Concorde medical Group, PLLC
    New York, New York 10016, United States
  • Kips Bay Endoscopy Center
    New York, New York 10016, United States
  • New York University Langone Medical Center
    New York, New York 10016, United States
  • NYU Clinical Cancer Center
    New York, New York 10016, United States
  • NYU Langone Medical Center
    New York, New York 10016, United States
  • NYU Medical Science Building
    New York, New York 10016, United States
  • Weill Cornell Medical College - New York Presbyterian Hospital
    New York, New York 10021, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • New York Presbyterian Hospital-Weill Cornell Medical College
    New York, New York 10065, United States
  • Weill Cornell Medical College-New York Presbyterian Hospital
    New York, New York 10065, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • UNC Hospitals
    Chapel Hill, North Carolina 27514, United States
  • UNC Hospitals Endoscopy Center at Meadowmont
    Chapel Hill, North Carolina 27517, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599-7064, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599-7080, United States
  • Digestive Disease Specialists, Inc.
    Oklahoma City, Oklahoma 73112, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Parkland Health and Hospital System
    Dallas, Texas 75235, United States
  • UT Southwestern Medical Center - CRU Aston
    Dallas, Texas 75390-8887, United States
  • UT Southwestern Medical Center-Clements University Hospital
    Dallas, Texas 75390, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Baylor College of Medicine- Baylor Medical Center
    Houston, Texas 77030, United States
  • Baylor St. Luke's Medical Center Endoscopy-McNair Campus
    Houston, Texas 77030, United States
  • Gulf Coast Research Group
    Houston, Texas 77098, United States
  • Lonestar Endoscopy, LLP
    Keller, Texas 76248, United States
  • Sagact, Pllc.
    San Antonio, Texas 78229, United States
  • Sagact, Pllc
    San Antonio, Texas 78229, United States
  • Lonestar Endoscopy, LLP
    Southlake, Texas 76092, United States
  • Texas Digestive Disease Consultants
    Southlake, Texas 76092, United States
  • Verity Research
    Fairfax, Virginia 22031, United States
  • Blue Ridge Medical Research
    Lynchburg, Virginia 24502, United States
  • McGuire DVAMC
    Richmond, Virginia 23249, United States
  • University of Washington
    Seattle, Washington 98195, United States
  • AKH Wien Universitaetsklinik fuer Innere Medizin III
    Wien, 1090, Austria
  • "Medical Center-1- Sevlievo" EOOD
    Sevlievo, Gabrovo 5400, Bulgaria
  • "MHAT-Blagoevgrad" AD
    Blagoevgrad, 2700, Bulgaria
  • MHAT Dobrich AD
    Dobrich, 9300, Bulgaria
  • MC Hipocrat-2000 OOD
    Haskovo, 6300, Bulgaria
  • MHAT Prof. Dr. Paraskev Stoyanov AD
    Lovech, 5500, Bulgaria
  • Medical Center Vitadar Consult OOD
    Ruse, 7000, Bulgaria
  • SHATPPD dr. Dimitar Gramatikov - Ruse EOOD
    Ruse, 7002, Bulgaria
  • "MC Asklepion - researches in human medicine"" EOOD
    Sofia, 1303, Bulgaria
  • "Acibadem City Clinic UMHAT" EOOD
    Sofia, 1784, Bulgaria
  • Hepato-Gastroenterologie HK, s.r.o.
    Hradec Kralove, 50012, Czechia
  • Fakultni nemocnice v Motole
    Praha 5, 150 06, Czechia
  • Nemocnice Slany, p.o.
    Slany, 274 01, Czechia
  • Nemocnice Strakonice, a.s., interni oddeleni
    Strakonice, 386 01, Czechia
  • Nordsjaellands Hospital Frederikssund
    Frederikssund, 3600, Denmark
  • Nordsjaellands Hospital Hilleroed
    Hilleroed, 3400, Denmark
  • Amager og Hvidovre Hospital
    Hvidovre, 2650, Denmark
  • Odense Universitetshospital
    Odense, 5000, Denmark
  • Research institute of Clinical Medicine
    Tbilisi, 0112, Georgia
  • The First University Clinic of TSMU
    Tbilisi, 0141, Georgia
  • Paian MED Research GmbH
    Berlin, 10318, Germany
  • Gastrostudien GbR
    Berlin, 10825, Germany
  • Krankenhaus Waldfriede e.V.
    Berlin, 14163, Germany
  • MVZ Dachau - Patientenzentrum
    Dachau, 85221, Germany
  • MVZ Dachau
    Dachau, 85221, Germany
  • Asklepios Westklinikum Hamburg
    Hamburg, 22559, Germany
  • Universitaetsklinikum Schleswig-Holstein
    Kiel, 24105, Germany
  • Eugastro GmbH
    Leipzig, 04103, Germany
  • Bekes Megyei Kozponti Korhaz, Rethy Pal Tagkorhaz
    Bekescsaba, 5600, Hungary
  • Semmelweis Egyetem, II. Belgyogyaszati Klinika
    Budapest, 1088, Hungary
  • Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak I. Belgyogyaszati Gasztroenterologiai Osztaly
    Budapest, 1125, Hungary
  • Pannonia Maganorvosi Centrum
    Budapest, 1136, Hungary
  • Tolna Megyei Balassa Janos Korhaz
    Szekszard, 7100, Hungary
  • Javorszky Odon Korhaz, Gasztroenterologia
    Vac, 2600, Hungary
  • Clalit Health Services
    Bat-Yam, 5962025, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 9103102, Israel
  • Diabetes and Endocrinology Unit
    Tel Aviv, 6203854, Israel
  • Migdal Hamea Clinic
    Tel Aviv, 6203854, Israel
  • IRCCS Saverio De Bellis
    Castellana Grotte, Bari 70013, Italy
  • AOU Sant'Orsola-Malpighi
    Bologna, BO 40138, Italy

Showing the first 100 of 189 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Fensome A, Ambler CM, Arnold E, Banker ME, Brown MF, Chrencik J, Clark JD, Dowty ME, Efremov IV, Flick A, Gerstenberger BS, Gopalsamy A, Hayward MM, Hegen M, Hollingshead BD, Jussif J, Knafels JD, Limburg DC, Lin D, Lin TH, Pierce BS, Saiah E, Sharma R, Symanowicz PT, Telliez JB, Trujillo JI, Vajdos FF, Vincent F, Wan ZK, Xing L, Yang X, Yang X, Zhang L. Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841). J Med Chem. 2018 Oct 11;61(19):8597-8612. doi: 10.1021/acs.jmedchem.8b00917. Epub 2018 Aug 16. PubMed 30113844 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in May 2021, 51 months.

Results were first posted in Jul 2022, 1 year 2 months after primary completion.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 51 months is above that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2016
First posted
Nov 8, 2016
StartActual
Feb 3, 2017
Primary completionActual
May 10, 2021
CompletionActual
May 10, 2021
Results first posted
Jul 21, 2022
Last update
Jul 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02958865
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 8, 2016
Start date
Feb 3, 2017
Primary completion
May 10, 2021
Completion
May 10, 2021
Results posted
Jul 21, 2022
Last update
Jul 21, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PF-06700841 · PF-06651600

Start the discussion